Search Results - "Thouvenot, E."

Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis by Thouvenot, E., Demattei, C., Lehmann, S., Maceski‐Maleska, A., Hirtz, C., Juntas‐Morales, R., Pageot, N., Esselin, F., Alphandéry, S., Vincent, T., Camu, W.

“…Background and purpose The prognostic value of serum neurofilament light chain (sNfL), a biomarker of neurodegeneration, compared to other prognostic factors…”
Get full text

Multiple sclerosis biomarkers: Helping the diagnosis? by Thouvenot, E.

“…Multiple sclerosis (MS) is a complex heterogeneous disease. Diagnostic criteria are based on symptoms, biomarkers, MRI data and exclusion of differential…”
Get full text

Should we treat patients with radiologically isolated syndrome (RIS)? Yes by Thouvenot, E.

Get full text

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study by Kuhle, J, Disanto, G, Dobson, R, Adiutori, R, Bianchi, L, Topping, J, Bestwick, JP, Meier, U-C, Marta, M, Costa, G Dalla, Runia, T, Evdoshenko, E, Lazareva, N, Thouvenot, E, Iaffaldano, P, Direnzo, V, Khademi, M, Piehl, F, Comabella, M, Sombekke, M, Killestein, J, Hegen, H, Rauch, S, D’Alfonso, S, Alvarez-Cermeño, JC, Kleinová, P, Horáková, D, Roesler, R, Lauda, F, Llufriu, S, Avsar, T, Uygunoglu, U, Altintas, A, Saip, S, Menge, T, Rajda, C, Bergamaschi, R, Moll, N, Khalil, M, Marignier, R, Dujmovic, I, Larsson, H, Malmestrom, C, Scarpini, E, Fenoglio, C, Wergeland, S, Laroni, A, Annibali, V, Romano, S, Martínez, AD, Carra, A, Salvetti, M, Uccelli, A, Torkildsen, Ø, Myhr, KM, Galimberti, D, Rejdak, K, Lycke, J, Frederiksen, JL, Drulovic, J, Confavreux, C, Brassat, D, Enzinger, C, Fuchs, S, Bosca, I, Pelletier, J, Picard, C, Colombo, E, Franciotta, D, Derfuss, T, Lindberg, RLP, Yaldizli, Ö, Vécsei, L, Kieseier, BC, Hartung, HP, Villoslada, P, Siva, A, Saiz, A, Tumani, H, Havrdová, E, Villar, LM, Leone, M, Barizzone, N, Deisenhammer, F, Teunissen, C, Montalban, X, Tintoré, M, Olsson, T, Trojano, M, Lehmann, S, Castelnovo, G, Lapin, S, Hintzen, R, Kappos, L, Furlan, R, Martinelli, V, Comi, G, Ramagopalan, SV, Giovannoni, G

“…Background and objective: We explored which clinical and biochemical variables predict conversion from clinically isolated syndrome (CIS) to clinically…”
Get full text

Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis by Hinsinger, G, Galéotti, N, Nabholz, N, Urbach, S, Rigau, V, Demattei, C, Lehmann, S, Camu, W, Labauge, P, Castelnovo, G, Brassat, D, Loussouarn, D, Salou, M, Laplaud, D, Casez, O, Bockaert, J, Marin, P, Thouvenot, E

“…Background: Despite sensitivity of MRI to diagnose multiple sclerosis (MS), prognostic biomarkers are still needed for optimized treatment. Objective: The…”
Get full text

Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study by Leurs, CE, Twaalfhoven, HAM, Lissenberg-Witte, BI, van Pesch, V, Dujmovic, I, Drulovic, J, Castellazzi, M, Bellini, T, Pugliatti, M, Kuhle, J, Villar, LM, Alvarez-Cermeño, JC, Alvarez-Lafuente, R, Hegen, H, Deisenhammer, F, Walchhofer, LM, Thouvenot, E, Comabella, M, Montalban, X, Vécsei, L, Rajda, C, Galimberti, D, Scarpini, E, Altintas, A, Rejdak, K, Frederiksen, JL, Pihl-Jensen, G, Jensen, PEH, Khalil, M, Voortman, MM, Fazekas, F, Saiz, A, La Puma, D, Vercammen, M, Vanopdenbosch, L, Uitdehaag, BMJ, Killestein, J, Bridel, C, Teunissen, C

“…Objective: To validate kappa free light chain (KFLC) and lambda free light chain (LFLC) indices as a diagnostic biomarker in multiple sclerosis (MS). Methods:…”
Get full text

Association between baseline pro-inflammatory cytokines and brain activation during social exclusion in patients with vulnerability to suicide and depressive disorder by Conejero, I, Jaussent, I., Cazals, A., Thouvenot, E., Mura, T., Le Bars, E., Guillaume, S., Squalli, S., Courtet, P., Olié, E.

“…•Baseline blood IL-1 decreases orbitofrontal activation in response to social exclusion.•Baseline blood IL-2 increases neural activation in response to social…”
Get full text

Protocol of comparison of the effects of single plasma exchange and double filtration plasmapheresis on peripheral lymphocyte phenotypes in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: a monocentric prospective study with single-case experimental design by Moranne, O, Ion, IM, Cezar, R, Messikh, Z, Prelipcean, C, Chkair, S, Thouvenot, E, Tran, Tu Anh, Corbeau, P, Chevallier, T

“…Abstract Background Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), a rare disorder affecting young adults, causes gradual weakness of the…”
Get full text

Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis by Thouvenot, E., Orsini, M., Daures, J.-P., Camu, W.

“…Background and purpose Vitamin D deficiency is a recognized risk factor for multiple sclerosis (MS) and is associated with increased disease activity. It has…”
Get full text

Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study by Cabre, Philippe, Mejdoubi, M., Jeannin, S., Merle, H., Plumelle, Y., Cavillon, G., Smadja, D., Marignier, R.

“…Objective Neuromyelitis optica (NMO) is a very severe autoimmune disorder of the central nervous system. It affects young subjects and has a poor prognosis…”
Get full text

Posttraumatic hemorrhagic dilated perivascular spaces by Renard, D., Freitag, C., Thouvenot, E.

Get full text

Long-term follow-up of neuromyelitis optica with a pediatric onset by COLLONGUES, N, MARIGNIER, R, AUDOIN, B, THOUVENOT, E, CAMU, W, BARROSO, B, RUET, A, BROCHET, B, VERMERSCH, P, CONFAVREUX, C, DE SEZE, J, ZEPHIR, H, PAPEIX, C, FONTAINE, B, BLANC, F, RODRIGUEZ, D, FLEURY, M, VUKUSIC, S, PELLETIER, J

“…Neuromyelitis optica (NMO) is a rare inflammatory disease. Average age at onset is 35 years. Few data exist on patients with pediatric-onset NMO (p-NMO), with…”
Get full text

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis by Lefort, M, Sharmin, S, Andersen, J B, Vukusic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, De Sèze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frenay, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Maurousset, A, Ben Nasr, H, Hankiewicz, K, Pottier, C, Maubeuge, N, Dimitri-Boulos, D, Nifle, C, Laplaud, D A, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand'Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Karabudak, R, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Koch-Henriksen, N, Sellebjerg, F, Soerensen, P S, Hilt Christensen, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Butzkueven, H, Magyari, M, Kalincik, T, Leray, E

“…Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two…”
Get full text

Severe bradycardia: An unreported adverse infusion-associated reaction (IAR) with alemtuzumab by Nerrant, E., Thouvenot, E., Castelnovo, G.

Get full text

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort by Outteryck, O., Ongagna, J.C., Brochet, B., Rumbach, L., Lebrun-Frenay, C., Debouverie, M., Zéphir, H., Ouallet, J.C., Berger, E., Cohen, M., Pittion, S., Laplaud, D., Wiertlewski, S., Cabre, P., Pelletier, J., Rico, A., Defer, G., Derache, N., Camu, W., Thouvenot, E., Moreau, T., Fromont, A., Tourbah, A., Labauge, P., Castelnovo, G., Clavelou, P., Casez, O., Hautecoeur, P., Papeix, C., Lubetzki, C., Fontaine, B., Couturier, N., Bohossian, N., Clanet, M., Vermersch, P., de Sèze, J., Brassat, D.

“…Background and purpose BIONAT is a French multicentric phase IV study of natalizumab (NTZ)‐treated relapsing−remitting multiple sclerosis (MS) patients. The…”
Get full text

Density heterogeneity and fluid–blood levels in patients aged over 55 with lobar hematoma by Renard, D., Waconge, A., Bouly, S., Castelli, C., Thouvenot, E.

“…Density heterogeneity and fluid–blood levels (FBLs) are frequently seen on acute CT scans of deep brain hemorrhage. Our aim was to analyze the density…”
Get full text

Cutaneous adverse events related to glatiramer acetate injection (copolymer-1, Copaxone®) by Kluger, N, Thouvenot, E, Camu, W, Guillot, B

Get full text

High-risk syndrome for neuromyelitis optica: a descriptive and comparative study by Collongues, N, Marignier, R, Zéphir, H, Blanc, F, Vukusic, S, Outteryck, O, Fleury, M, Ruet, A, Borgel, F, Thouvenot, E, Moreau, T, Defer, G, Derache, N, Pelletier, J, Audoin, B, Debouverie, M, Labauge, P, Gout, O, Camu, W, Brassat, D, Brochet, B, Vermersch, P, Confavreux, C, Seze, J de

“…Background: Neuromyelitis optica (NMO) frequently begins with a monofocal episode of optic neuritis or myelitis. A concept named high-risk syndrome (HRS) for…”
Get full text

DIABETES INSIPIDUS AS A FIRST MANIFESTATION IN MULTIPLE SCLEROSIS by THOUVENOT, E, SCHMIDT, C, HEROUM, C, CARLANDER, B, BONAFE, A, CAMU, W

Get full text

Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay by De Vidi, I, Boursier, G, Delouche, N, Portalès, P, Cadars, E, Bouthier, M, Mettling, C, Lin, Y.L, Thouvenot, E, Carlander, B, Camu, W, Antel, J.P, Bar-Or, A, Zephir, H, Vermersch, P, De Seze, J, Corbeau, P, Eliaou, J.F, Vincent, T

“…Abstract NMO-IgG is a specific biomarker of neuromyelitis optica (NMO) that targets the aquaporin-4 (AQP4) water channel protein. The current gold standard for…”
Get full text